… for morbid obesity used in the current study (BMI ≥35 mg/kg … BL/BLI dosing in patients who
are morbidly obese and have P … –based dosing coupled with modified dosing administrations …

… activity of piperacillin/tazobactam (TZP) dosing regimens … , and piperacillin/tazobactam
(TZP) could play a role in this context and may reduce selection pressure. Piperacillin/tazobactam …

… /TAZO in critically ill obese patients immediately after the first administered dose. In the context
of … maximization of PIP/TAZO dose at baseline to rapidly saturate increased V d in obese …

… piperacillin–tazobactam therapy ≤ 72 h before inclusion, and were managed with a central
venous and/or arterial catheter. Patients … Dose and duration of piperacillin–tazobactam were …

… In patients performing more than one TDM-guided ECPA for piperacillin–tazobactam
dosing … (the first one before any dosage adjustment and the subsequent ones after eventual …

… dosing in HFIM, piperacillin/tazobactam and meropenem stock solutions were prepared from
piperacillin/tazobactam (… ) and meropenem (Meropenem, 1000 mg, Fresenius Kabi Pty Ltd, …

… For example, in the presence of 8/8 mg/L piperacillin-tazobactam, the GRM copy number
per cell increased approximately 10-fold to >90, which reflects at least an ~800-kb increase in …

… -based dose optimisation of piperacillin/tazobactam to improve outcome in patients with
sepsis (… on CRRT, and those on ECMO and/or morbid obesity. Prospective studies focusing on …

… Patients were included only if: the first piperacillin–tazobactam dose was administered in the
… of the therapy was at least 48 h, and the patient was not admitted to the intensive care unit. …

… for morbidly obese individuals. The peculiar interactions of several antibiotics are affected by
morbid obesity (… in normal renal functioning morbidly obese patients were developed. It was …